Mucin Glycosylating Enzymes in Head and Neck Cancers

Expression of Mucin Glycosylating Enzymes in Head and Neck Cancers and Its Correlation With Clinico-pathological Parameters.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01976377

Enrollment

200

Registered

2013-11-05

Start date

2013-10-31

Completion date

2017-10-31

Last updated

2016-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glycosyltion Enzymes and Function Abnormalities

Brief summary

Head and neck squamous cell carcinoma(HNSCC) is the fourth common malignancy in Taiwan. It accounts for 5.8% of all cancers and causes 2,463 deaths per year. Aberrant glycosylation is the hallmark of most human cancers, including HNSCC, and affects many cellular properties. This study is aimed at exploring the role of mucin glycosylating enzymes in HNSCC.

Detailed description

Glycosylation is the most common post-translational modification of proteins. Aberrant glycosylation is the hallmark of most human cancers and affect many cellular properties, including cell proliferation, apoptosis, differentiation, transformation, migration and immune response. Though widely explored in various human cancers, the role of mucin glycosylating enzymes in HNSCC has not been elucidated. Our aims is to analyze the expression patterns of mucin glycosylating enzymes in HNSCC tissues. Furthermore, we will correlate the expression levels of mucin glycosylating enzymes with clinical characteristics of HNSCC patients.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Head and neck cancer patients receiving operation in National Taiwan University Hospital

Exclusion criteria

* Recurrence or non-operable patients

Design outcomes

Primary

Measure	Time frame
Measure the expression of mucin glycosylating in head and neck cancer	1~5 years after patient received surgery

Countries

Taiwan

Contacts

Primary ContactPei-Jen Lou, M.D, Ph.D

pjlou@ntu.edu.tw886-972651527

Backup ContactMei-Chun Lin

b91401051@ntu.edu.tw886-978261268

Outcome results